SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
- 1 May 2021
- journal article
- letter
- Published by Elsevier in European Journal of Cancer
- Vol. 148, 121-123
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?European Journal of Cancer, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1Annals of Oncology, 2020
- Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint InhibitorsImmunotherapy, 2020
- Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patientsAmerican Journal of Infection Control, 2016